Christine Moore Bio - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Christine Moore Bio


Christine Moore Bio 
Dr. Moore is the currently the Acting Director of FDA's Office of New Drug Quality Assessment. Christine has been with the FDA since 2004 and has been at the forefront of FDA's Quality by Design efforts including being a member of the expert working group for ICH Q8(R). Prior to joining the FDA, she worked for 10 years in API process development and scale-up at Pfizer and Searle/Pharmacia. Her background is in chemical and biochemical engineering, with degrees from Northwestern University and Massachusetts Institute of Technology.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here